- Home
- CHRS vs SJT Comparison
CHRS vs SJT Comparison
Compare CHRS & SJT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SJT
- Stock Information
- Founded
- CHRS 2010
- SJT 1980
- Country
- CHRS United States
- SJT United States
- Employees
- CHRS N/A
- SJT N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SJT Oil & Gas Production
- Sector
- CHRS Health Care
- SJT Energy
- Exchange
- CHRS Nasdaq
- SJT Nasdaq
- Market Cap
- CHRS 84.2M
- SJT 280.6M
- IPO Year
- CHRS 2014
- SJT N/A
- Fundamental
- Price
- CHRS $0.88
- SJT $5.96
- Analyst Decision
- CHRS Buy
- SJT
- Analyst Count
- CHRS 3
- SJT 0
- Target Price
- CHRS $4.68
- SJT N/A
- AVG Volume (30 Days)
- CHRS 1.3M
- SJT 225.1K
- Earning Date
- CHRS 08-07-2025
- SJT 08-13-2025
- Dividend Yield
- CHRS N/A
- SJT N/A
- EPS Growth
- CHRS N/A
- SJT N/A
- EPS
- CHRS N/A
- SJT 0.02
- Revenue
- CHRS $272,251,000.00
- SJT $1,931,777.00
- Revenue This Year
- CHRS N/A
- SJT N/A
- Revenue Next Year
- CHRS $99.43
- SJT N/A
- P/E Ratio
- CHRS N/A
- SJT $262.86
- Revenue Growth
- CHRS 19.87
- SJT N/A
- 52 Week Low
- CHRS $0.66
- SJT $3.21
- 52 Week High
- CHRS $2.43
- SJT $7.22
- Technical
- Relative Strength Index (RSI)
- CHRS 55.66
- SJT 46.91
- Support Level
- CHRS $0.82
- SJT $5.95
- Resistance Level
- CHRS $0.94
- SJT $6.42
- Average True Range (ATR)
- CHRS 0.06
- SJT 0.22
- MACD
- CHRS 0.01
- SJT 0.00
- Stochastic Oscillator
- CHRS 67.00
- SJT 39.00
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.